Ryan T. Koehler
Research Subjects
Ryan T. Koehler has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
George Karlin-Neumann
Digital Biology Center, Bio-Rad Laboratories, Pleasanton, California, United States of America
3 shared publicationsHugo O. Villar
Telik, Inc
3 shared publicationsNicolas Peyret
3 shared publications- Ajay A. Sapre
Parse Biosciences, Seattle, USA
2 shared publications Alec Salvino
Parse Biosciences, Seattle, USA
2 shared publications- Alexa Suyama
Parse Biosciences, Seattle, USA
2 shared publications
Latest Publications
- 1 July 2026
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 191 (Supplement) , 673-682
Artificial Intelligence/Machine Learning–Driven cfDNA Methylation Blood Test for Early Cancer Detection in Military Personnel With Environmental Toxin Exposure
Introduction: Military personnel face heightened cancer risks from exposure to burn-pit emissions, per- and polyfluoroalkyl substances (PFAS), jet fuel, and radiation. Veterans show elevated malignancy rates, and active-duty personnel remain vulnerable because of ongoing operational exposures, underscoring the need for early detection. Traditional screening methods are invasive and have limited sensitivity for early-stage disease. This study evaluates the feasibility of artificial intelligence/machine learning (AI/ML)-based cell-free DNA (cfDNA) methylation analysis for early cancer detection using publicly available civilian datasets, to inform future application in high-risk military populations. Materials and Methods: A Machine-Learning driven cfDNA methylation classifier framework was developed for early, minimally-invasive detection of cancers associated with toxic and occupational exposures. The platform uses bisulfite-sequenced data to identify differential methylation signatures that distinguish early stage hepatocellular carcinoma (HCC) from chronic liver disease and healthy controls. Proof-of-concept studies were conducted on public datasets for hepatocellular carcinoma (HCC) and esophageal cancer. Three cfDNA datasets (GSE93203, GSE63775, and PRJCA001372) were used for model training and k-fold cross-validation, and an independent WGBS liver-tissue dataset (PRJNA984754) served as a blind cross-assay validation set. Framework extensibility to other cancers was assessed through the EpiPanGI-Dx esophageal-cancer dataset (ESCC training, EAC validation). Results: Across 3 HCC models, internal cross-validation achieved 84%-94% accuracy (AUC 0.80-0.88). On the independent WGBS dataset validated against the 3 trained models, classifiers generalized with 83%-100% accuracy (AUC 0.80-1.00). Clinical validation using biobank cfDNA plasma samples from early-stage hepatocellular carcinoma and cirrhosis controls is ongoing. The esophageal cancer model reproduced published performance (AUC 0.94 for ESCC, 0.90 for EAC), demonstrating generalizability beyond HCC. Conclusion: The cfDNA methylation–based AI/ML platform is promising for early multi-cancer detection in environmentally exposed military populations. Early results demonstrate feasibility and justify expansion to additional cancers, and larger clinical validation studies, potentially enhancing survivability through earlier intervention.
- 1 July 2026
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 191 (Supplement) , 673-682
Artificial Intelligence/Machine Learning–Driven cfDNA Methylation Blood Test for Early Cancer Detection in Military Personnel With Environmental Toxin Exposure
Introduction: Military personnel face heightened cancer risks from exposure to burn-pit emissions, per- and polyfluoroalkyl substances (PFAS), jet fuel, and radiation. Veterans show elevated malignancy rates, and active-duty personnel remain vulnerable because of ongoing operational exposures, underscoring the need for early detection. Traditional screening methods are invasive and have limited sensitivity for early-stage disease. This study evaluates the feasibility of artificial intelligence/machine learning (AI/ML)-based cell-free DNA (cfDNA) methylation analysis for early cancer detection using publicly available civilian datasets, to inform future application in high-risk military populations. Materials and Methods: A Machine-Learning driven cfDNA methylation classifier framework was developed for early, minimally-invasive detection of cancers associated with toxic and occupational exposures. The platform uses bisulfite-sequenced data to identify differential methylation signatures that distinguish early stage hepatocellular carcinoma (HCC) from chronic liver disease and healthy controls. Proof-of-concept studies were conducted on public datasets for hepatocellular carcinoma (HCC) and esophageal cancer. Three cfDNA datasets (GSE93203, GSE63775, and PRJCA001372) were used for model training and k-fold cross-validation, and an independent WGBS liver-tissue dataset (PRJNA984754) served as a blind cross-assay validation set. Framework extensibility to other cancers was assessed through the EpiPanGI-Dx esophageal-cancer dataset (ESCC training, EAC validation). Results: Across 3 HCC models, internal cross-validation achieved 84%-94% accuracy (AUC 0.80-0.88). On the independent WGBS dataset validated against the 3 trained models, classifiers generalized with 83%-100% accuracy (AUC 0.80-1.00). Clinical validation using biobank cfDNA plasma samples from early-stage hepatocellular carcinoma and cirrhosis controls is ongoing. The esophageal cancer model reproduced published performance (AUC 0.94 for ESCC, 0.90 for EAC), demonstrating generalizability beyond HCC. Conclusion: The cfDNA methylation–based AI/ML platform is promising for early multi-cancer detection in environmentally exposed military populations. Early results demonstrate feasibility and justify expansion to additional cancers, and larger clinical validation studies, potentially enhancing survivability through earlier intervention.
- Open Access
A single-cell cytokine dictionary of human peripheral blood
Cytokines orchestrate immune responses, yet we still lack a comprehensive understanding of their specific effects across human immune cells due to their pleiotropy, context dependence and extensive functional redundancy. Here, we present a Human Cytokine Dictionary, created from high-resolution single-cell transcriptomes of 9,697,974 human peripheral blood mononuclear cells (PBMC) from 12 donors stimulated in vitro with 90 different cytokines. We describe donor-specific response variation and uncover robust consensus cytokine signatures across individuals. We then delineate similarities between cytokine response profiles, and derive cytokine-induced immune programs that organize responsive genes into data-driven, biologically interpretable functional modules. By integrating cell type-specific responses with expression of cytokines, we infer higher-order cell-to-cell and cytokine-to-cytokine communication networks exemplified by an IL-32-β-initiated signaling cascade, which rewires myeloid programs by inducing neutrophil-recruiting factors while suppressing Th1-responses and promoting IL-10-family cytokines. Finally, we show how the Human Cytokine Dictionary enables the interpretation of cytokine-driven immune responses in other studies and disease contexts, including systemic lupus erythematosus, multiple sclerosis, and non-small cell lung carcinoma. Together, the Human Cytokine Dictionary constitutes the first comprehensive cell type-resolved transcriptional screen of human cytokine responses and provides an essential open-access, easy-to-use community resource with accompanying software package to advance our understanding of cytokine biology in human disease and guide therapeutic discovery.
Open AccessA single-cell cytokine dictionary of human peripheral blood
Cytokines orchestrate immune responses, yet we still lack a comprehensive understanding of their specific effects across human immune cells due to their pleiotropy, context dependence and extensive functional redundancy. Here, we present a Human Cytokine Dictionary, created from high-resolution single-cell transcriptomes of 9,697,974 human peripheral blood mononuclear cells (PBMC) from 12 donors stimulated in vitro with 90 different cytokines. We describe donor-specific response variation and uncover robust consensus cytokine signatures across individuals. We then delineate similarities between cytokine response profiles, and derive cytokine-induced immune programs that organize responsive genes into data-driven, biologically interpretable functional modules. By integrating cell type-specific responses with expression of cytokines, we infer higher-order cell-to-cell and cytokine-to-cytokine communication networks exemplified by an IL-32-β-initiated signaling cascade, which rewires myeloid programs by inducing neutrophil-recruiting factors while suppressing Th1-responses and promoting IL-10-family cytokines. Finally, we show how the Human Cytokine Dictionary enables the interpretation of cytokine-driven immune responses in other studies and disease contexts, including systemic lupus erythematosus, multiple sclerosis, and non-small cell lung carcinoma. Together, the Human Cytokine Dictionary constitutes the first comprehensive cell type-resolved transcriptional screen of human cytokine responses and provides an essential open-access, easy-to-use community resource with accompanying software package to advance our understanding of cytokine biology in human disease and guide therapeutic discovery.
- Open Access
- 12 December 2025
- Published by Springer Nature in Research Square
A single-cell cytokine dictionary of human peripheral blood
Cytokines orchestrate immune responses, yet we still lack a comprehensive understanding of their specific effects across human immune cells due to their pleiotropy, context dependence and extensive functional redundancy. Here, we present a Human Cytokine Dictionary, created from high-resolution single-cell transcriptomes of 9,697,974 human peripheral blood mononuclear cells (PBMC) from 12 donors stimulated in vitro with 90 different cytokines. We describe donor-specific response variation and uncover robust consensus cytokine signatures across individuals. We then delineate similarities between cytokine response profiles, and derive cytokine-induced immune programs that organize responsive genes into data-driven, biologically interpretable functional modules. By integrating cell type-specific responses with expression of cytokines, we infer higher-order cell-to-cell and cytokine-to-cytokine communication networks exemplified by an IL-32-β-initiated signaling cascade, which rewires myeloid programs by inducing neutrophil-recruiting factors while suppressing Th1-responses and promoting IL-10-family cytokines. Finally, we show how the Human Cytokine Dictionary enables the interpretation of cytokine-driven immune responses in other studies and disease contexts, including systemic lupus erythematosus, multiple sclerosis, and non-small cell lung carcinoma. Together, the Human Cytokine Dictionary constitutes the first comprehensive cell type-resolved transcriptional screen of human cytokine responses and provides an essential open-access, easy-to-use community resource with accompanying software package to advance our understanding of cytokine biology in human disease and guide therapeutic discovery.
- 12 December 2025
- Published by Springer Nature in Research Square
Open AccessA single-cell cytokine dictionary of human peripheral blood
Cytokines orchestrate immune responses, yet we still lack a comprehensive understanding of their specific effects across human immune cells due to their pleiotropy, context dependence and extensive functional redundancy. Here, we present a Human Cytokine Dictionary, created from high-resolution single-cell transcriptomes of 9,697,974 human peripheral blood mononuclear cells (PBMC) from 12 donors stimulated in vitro with 90 different cytokines. We describe donor-specific response variation and uncover robust consensus cytokine signatures across individuals. We then delineate similarities between cytokine response profiles, and derive cytokine-induced immune programs that organize responsive genes into data-driven, biologically interpretable functional modules. By integrating cell type-specific responses with expression of cytokines, we infer higher-order cell-to-cell and cytokine-to-cytokine communication networks exemplified by an IL-32-β-initiated signaling cascade, which rewires myeloid programs by inducing neutrophil-recruiting factors while suppressing Th1-responses and promoting IL-10-family cytokines. Finally, we show how the Human Cytokine Dictionary enables the interpretation of cytokine-driven immune responses in other studies and disease contexts, including systemic lupus erythematosus, multiple sclerosis, and non-small cell lung carcinoma. Together, the Human Cytokine Dictionary constitutes the first comprehensive cell type-resolved transcriptional screen of human cytokine responses and provides an essential open-access, easy-to-use community resource with accompanying software package to advance our understanding of cytokine biology in human disease and guide therapeutic discovery.
- Open Access
A Generalizable Machine Learning Framework for cfDNA based Early Detection of Hepatocellular Carcinoma: a Feasibility Study with Preclinical Validation
PURPOSE: Early detection of hepatocellular carcinoma (HCC) is critical for improving patient outcomes, yet current screening tools lack sensitivity and specificity. We demonstrate a flexible machine learning framework for HCC detection using methylation profiles from bisulfite sequencing across multiple assay platforms and sample types. The framework supports a “split-and-filter” approach that routes each sequenced sample to an assay-matched classifier without requiring cross-assay feature compatibility. PATIENTS AND METHODS: We constructed assay-specific classifiers using four independent public methylation datasets (∼2,500 total samples) representing distinct bisulfite-sequencing technologies: GSE93203 (MCB-targeted hypermethylation), GSE63775 (MCTA-Seq tandem-repeat hypermethylation), PRJCA001372 (HBV-integration–associated hypomethylation), and the HCC subset of GSE149438 (EpiPanGIDX - DMR-level hyper- and hypomethylation). Separate models were trained using using the biologically relevant features for each dataset and evaluated in two independent blind validation datasets: published tissue WGBS (24 samples: 12 early-stage HCC, 12 matched controls; PRJNA984754) and a new preclinical plasma cfDNA WGBS dataset (12 samples) generated at a commercial sequencing laboratory. Limited feature overlap among assays precluded a single unified model. Instead, overlapping features enabled construction of a proof-of-concept meta-classifier for sample routing across assay-specific models. RESULTS: Assay-specific cfDNA models, trained independently on CpG sites from original publications, were evaluated using the biopsy(tissue) dataset and a new plasma dataset as blind validation. All four assay-specific models generalized well to the validation data, with accuracies of 83.5%-100%. In the validation with the plasma cfDNA samples, the best-performing classifier (among XGBoost, Random Forest, and Logistic Regression) for each public dataset achieved 80–100% sensitivity and 86–100% specificity, with all Stage 2 cases correctly detected across models. The single Stage 1A case showed methylation levels overlapping with cirrhotic controls, consistent with biological expectations. Despite this, a couple of the models predicted this correctly, showing greater sensitivity to Stage 1 cancer. CONCLUSION: A generalizable framework for early detection of HCC composed of assay-specific classifiers and a meta-classifier is described. This architecture readily accommodates addition of new assays via feature-matched models and meta-classifications. Larger, prospectively collected studies are necessary to confirm performance and enable clinical translation.
Open AccessA Generalizable Machine Learning Framework for cfDNA based Early Detection of Hepatocellular Carcinoma: a Feasibility Study with Preclinical Validation
PURPOSE: Early detection of hepatocellular carcinoma (HCC) is critical for improving patient outcomes, yet current screening tools lack sensitivity and specificity. We demonstrate a flexible machine learning framework for HCC detection using methylation profiles from bisulfite sequencing across multiple assay platforms and sample types. The framework supports a “split-and-filter” approach that routes each sequenced sample to an assay-matched classifier without requiring cross-assay feature compatibility. PATIENTS AND METHODS: We constructed assay-specific classifiers using four independent public methylation datasets (∼2,500 total samples) representing distinct bisulfite-sequencing technologies: GSE93203 (MCB-targeted hypermethylation), GSE63775 (MCTA-Seq tandem-repeat hypermethylation), PRJCA001372 (HBV-integration–associated hypomethylation), and the HCC subset of GSE149438 (EpiPanGIDX - DMR-level hyper- and hypomethylation). Separate models were trained using using the biologically relevant features for each dataset and evaluated in two independent blind validation datasets: published tissue WGBS (24 samples: 12 early-stage HCC, 12 matched controls; PRJNA984754) and a new preclinical plasma cfDNA WGBS dataset (12 samples) generated at a commercial sequencing laboratory. Limited feature overlap among assays precluded a single unified model. Instead, overlapping features enabled construction of a proof-of-concept meta-classifier for sample routing across assay-specific models. RESULTS: Assay-specific cfDNA models, trained independently on CpG sites from original publications, were evaluated using the biopsy(tissue) dataset and a new plasma dataset as blind validation. All four assay-specific models generalized well to the validation data, with accuracies of 83.5%-100%. In the validation with the plasma cfDNA samples, the best-performing classifier (among XGBoost, Random Forest, and Logistic Regression) for each public dataset achieved 80–100% sensitivity and 86–100% specificity, with all Stage 2 cases correctly detected across models. The single Stage 1A case showed methylation levels overlapping with cirrhotic controls, consistent with biological expectations. Despite this, a couple of the models predicted this correctly, showing greater sensitivity to Stage 1 cancer. CONCLUSION: A generalizable framework for early detection of HCC composed of assay-specific classifiers and a meta-classifier is described. This architecture readily accommodates addition of new assays via feature-matched models and meta-classifications. Larger, prospectively collected studies are necessary to confirm performance and enable clinical translation.
- Open Access
- 15 January 2018
- Published by Springer Nature in npj Genomic Medicine
- Vol. 3 (1) , 1-10
A robust targeted sequencing approach for low input and variable quality DNA from clinical samples
Next-generation deep sequencing of gene panels is being adopted as a diagnostic test to identify actionable mutations in cancer patient samples. However, clinical samples, such as formalin-fixed, paraffin-embedded specimens, frequently provide low quantities of degraded, poor quality DNA. To overcome these issues, many sequencing assays rely on extensive PCR amplification leading to an accumulation of bias and artifacts. Thus, there is a need for a targeted sequencing assay that performs well with DNA of low quality and quantity without relying on extensive PCR amplification. We evaluate the performance of a targeted sequencing assay based on Oligonucleotide Selective Sequencing, which permits the enrichment of genes and regions of interest and the identification of sequence variants from low amounts of damaged DNA. This assay utilizes a repair process adapted to clinical FFPE samples, followed by adaptor ligation to single stranded DNA and a primer-based capture technique. Our approach generates sequence libraries of high fidelity with reduced reliance on extensive PCR amplification—this facilitates the accurate assessment of copy number alterations in addition to delivering accurate single nucleotide variant and insertion/deletion detection. We apply this method to capture and sequence the exons of a panel of 130 cancer-related genes, from which we obtain high read coverage uniformity across the targeted regions at starting input DNA amounts as low as 10 ng per sample. We demonstrate the performance using a series of reference DNA samples, and by identifying sequence variants in DNA from matched clinical samples originating from different tissue types.
- 15 January 2018
- Published by Springer Nature in npj Genomic Medicine
- Vol. 3 (1) , 1-10
Open AccessA robust targeted sequencing approach for low input and variable quality DNA from clinical samples
Next-generation deep sequencing of gene panels is being adopted as a diagnostic test to identify actionable mutations in cancer patient samples. However, clinical samples, such as formalin-fixed, paraffin-embedded specimens, frequently provide low quantities of degraded, poor quality DNA. To overcome these issues, many sequencing assays rely on extensive PCR amplification leading to an accumulation of bias and artifacts. Thus, there is a need for a targeted sequencing assay that performs well with DNA of low quality and quantity without relying on extensive PCR amplification. We evaluate the performance of a targeted sequencing assay based on Oligonucleotide Selective Sequencing, which permits the enrichment of genes and regions of interest and the identification of sequence variants from low amounts of damaged DNA. This assay utilizes a repair process adapted to clinical FFPE samples, followed by adaptor ligation to single stranded DNA and a primer-based capture technique. Our approach generates sequence libraries of high fidelity with reduced reliance on extensive PCR amplification—this facilitates the accurate assessment of copy number alterations in addition to delivering accurate single nucleotide variant and insertion/deletion detection. We apply this method to capture and sequence the exons of a panel of 130 cancer-related genes, from which we obtain high read coverage uniformity across the targeted regions at starting input DNA amounts as low as 10 ng per sample. We demonstrate the performance using a series of reference DNA samples, and by identifying sequence variants in DNA from matched clinical samples originating from different tissue types.
- 15 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (14_Supplem) , 2712
Abstract 2712: Joint somatic mutation and germline variant identification and scoring from tumor molecular profiling and ct-DNA monitoring of cancer patients by high-throughput sequencing
Cancer tumor profiling by targeted resequencing of actionable cancer genes is rapidly becoming the standard approach for selecting targeted therapies and clinical trials in refractory cancer patients. In this clinical scenario, a tumor sample is obtained from an FFPE block and sequenced by targeted next-generation sequencing (NGS) to uncover actionable somatic mutations in relevant cancer genes. Some of the challenges that arise in analyzing tumor-derived NGS data include distinguishing between somatic and germline variants in the absence of normal tissue data, recognizing pathogenic germline variants, and identifying sequencing errors (which occur at about 0.5% rate). Additional challenges arise when considering other clinical applications of NGS such as sequencing cell-free tumor DNA (cf-DNA) from plasma samples to monitor disease response or disease recurrence. Here we present a principled approach to identify both single-nucleotide and small insertion/deletion somatic mutations and germline variants from NGS data of tumor tissue that leverages the allelic fraction patterns in tumors and prior information from external databases through the use of a Bayesian Network algorithm. Our approach allows us to score each putative mutation or variant with respect to its probability of belonging to each variant class, versus classification as a sequencing error. The method enables the joint calling of related samples form the same patient, such as cases where a cf-DNA sample and primary tumor sample are both profiled improving sensitivity and specificity. We validated our method by analyzing data obtained with the TOMA OS-Seq targeted sequencing RUO assay for 98 cancer genes from a mixture of well-known genomes, patient case triads (where normal, tumor and cf-DNA are available), and a retrospective analysis of tumor patient data that underwent clinical tumor profiling for therapy selection. Citation Format: Francisco M. De La Vega, Ryan T. Koehler, Yannick Pouliot, Yosr Bouhlal, Austin So, Federico Goodsaid, Sean Irvine, Len Trigg, Lincoln Nadauld. Joint somatic mutation and germline variant identification and scoring from tumor molecular profiling and ct-DNA monitoring of cancer patients by high-throughput sequencing. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2712.
- 15 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (14_Supplem) , 2712
Abstract 2712: Joint somatic mutation and germline variant identification and scoring from tumor molecular profiling and ct-DNA monitoring of cancer patients by high-throughput sequencing
Cancer tumor profiling by targeted resequencing of actionable cancer genes is rapidly becoming the standard approach for selecting targeted therapies and clinical trials in refractory cancer patients. In this clinical scenario, a tumor sample is obtained from an FFPE block and sequenced by targeted next-generation sequencing (NGS) to uncover actionable somatic mutations in relevant cancer genes. Some of the challenges that arise in analyzing tumor-derived NGS data include distinguishing between somatic and germline variants in the absence of normal tissue data, recognizing pathogenic germline variants, and identifying sequencing errors (which occur at about 0.5% rate). Additional challenges arise when considering other clinical applications of NGS such as sequencing cell-free tumor DNA (cf-DNA) from plasma samples to monitor disease response or disease recurrence. Here we present a principled approach to identify both single-nucleotide and small insertion/deletion somatic mutations and germline variants from NGS data of tumor tissue that leverages the allelic fraction patterns in tumors and prior information from external databases through the use of a Bayesian Network algorithm. Our approach allows us to score each putative mutation or variant with respect to its probability of belonging to each variant class, versus classification as a sequencing error. The method enables the joint calling of related samples form the same patient, such as cases where a cf-DNA sample and primary tumor sample are both profiled improving sensitivity and specificity. We validated our method by analyzing data obtained with the TOMA OS-Seq targeted sequencing RUO assay for 98 cancer genes from a mixture of well-known genomes, patient case triads (where normal, tumor and cf-DNA are available), and a retrospective analysis of tumor patient data that underwent clinical tumor profiling for therapy selection. Citation Format: Francisco M. De La Vega, Ryan T. Koehler, Yannick Pouliot, Yosr Bouhlal, Austin So, Federico Goodsaid, Sean Irvine, Len Trigg, Lincoln Nadauld. Joint somatic mutation and germline variant identification and scoring from tumor molecular profiling and ct-DNA monitoring of cancer patients by high-throughput sequencing. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2712.
- Open Access
- 4 March 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0118270
A Rapid Molecular Approach for Chromosomal Phasing
Determining the chromosomal phase of pairs of sequence variants – the arrangement of specific alleles as haplotypes – is a routine challenge in molecular genetics. Here we describe Drop-Phase, a molecular method for quickly ascertaining the phase of pairs of DNA sequence variants (separated by 1-200 kb) without cloning or manual single-molecule dilution. In each Drop-Phase reaction, genomic DNA segments are isolated in tens of thousands of nanoliter-sized droplets together with allele-specific fluorescence probes, in a single reaction well. Physically linked alleles partition into the same droplets, revealing their chromosomal phase in the co-distribution of fluorophores across droplets. We demonstrated the accuracy of this method by phasing members of trios (revealing 100% concordance with inheritance information), and demonstrate a common clinical application by phasing CFTR alleles at genomic distances of 11–116 kb in the genomes of cystic fibrosis patients. Drop-Phase is rapid (requiring less than 4 hours), scalable (to hundreds of samples), and effective at long genomic distances (200 kb).
- 4 March 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0118270
Open AccessA Rapid Molecular Approach for Chromosomal Phasing
Determining the chromosomal phase of pairs of sequence variants – the arrangement of specific alleles as haplotypes – is a routine challenge in molecular genetics. Here we describe Drop-Phase, a molecular method for quickly ascertaining the phase of pairs of DNA sequence variants (separated by 1-200 kb) without cloning or manual single-molecule dilution. In each Drop-Phase reaction, genomic DNA segments are isolated in tens of thousands of nanoliter-sized droplets together with allele-specific fluorescence probes, in a single reaction well. Physically linked alleles partition into the same droplets, revealing their chromosomal phase in the co-distribution of fluorophores across droplets. We demonstrated the accuracy of this method by phasing members of trios (revealing 100% concordance with inheritance information), and demonstrate a common clinical application by phasing CFTR alleles at genomic distances of 11–116 kb in the genomes of cystic fibrosis patients. Drop-Phase is rapid (requiring less than 4 hours), scalable (to hundreds of samples), and effective at long genomic distances (200 kb).
- 3 November 2013
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 85 (23) , 11619-11627
Multiplexed Target Detection Using DNA-Binding Dye Chemistry in Droplet Digital PCR
Two years ago, we described the first droplet digital PCR (ddPCR) system aimed at empowering all researchers with a tool that removes the substantial uncertainties associated with using the analogue standard, quantitative real-time PCR (qPCR). This system enabled TaqMan hydrolysis probe-based assays for the absolute quantification of nucleic acids. Due to significant advancements in droplet chemistry and buoyed by the multiple benefits associated with dye-based target detection, we have created a “second generation” ddPCR system compatible with both TaqMan-probe and DNA-binding dye detection chemistries. Herein, we describe the operating characteristics of DNA-binding dye based ddPCR and offer a side-by-side comparison to TaqMan probe detection. By partitioning each sample prior to thermal cycling, we demonstrate that it is now possible to use a DNA-binding dye for the quantification of multiple target species from a single reaction. The increased resolution associated with partitioning also made it possible to visualize and account for signals arising from nonspecific amplification products. We expect that the ability to combine the precision of ddPCR with both DNA-binding dye and TaqMan probe detection chemistries will further enable the research community to answer complex and diverse genetic questions.
- 3 November 2013
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 85 (23) , 11619-11627
Multiplexed Target Detection Using DNA-Binding Dye Chemistry in Droplet Digital PCR
Two years ago, we described the first droplet digital PCR (ddPCR) system aimed at empowering all researchers with a tool that removes the substantial uncertainties associated with using the analogue standard, quantitative real-time PCR (qPCR). This system enabled TaqMan hydrolysis probe-based assays for the absolute quantification of nucleic acids. Due to significant advancements in droplet chemistry and buoyed by the multiple benefits associated with dye-based target detection, we have created a “second generation” ddPCR system compatible with both TaqMan-probe and DNA-binding dye detection chemistries. Herein, we describe the operating characteristics of DNA-binding dye based ddPCR and offer a side-by-side comparison to TaqMan probe detection. By partitioning each sample prior to thermal cycling, we demonstrate that it is now possible to use a DNA-binding dye for the quantification of multiple target species from a single reaction. The increased resolution associated with partitioning also made it possible to visualize and account for signals arising from nonspecific amplification products. We expect that the ability to combine the precision of ddPCR with both DNA-binding dye and TaqMan probe detection chemistries will further enable the research community to answer complex and diverse genetic questions.
- Open Access
- 1 June 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (6) , 991-994
Droplet Digital PCR Measurement of HER2 Copy Number Alteration in Formalin-Fixed Paraffin-Embedded Breast Carcinoma Tissue
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) testing is routinely performed by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) analyses for all new cases of invasive breast carcinoma. IHC is easier to perform, but analysis can be subjective and variable. FISH offers better diagnostic accuracy and added confidence, particularly when it is used to supplement weak IHC signals, but it is more labor intensive and costly than IHC. We examined the performance of droplet digital PCR (ddPCR) as a more precise and less subjective alternative for quantifying HER2 DNA amplification. METHODS: Thirty-nine cases of invasive breast carcinoma containing ≥30% tumor were classified as positive or negative for HER2 by IHC, FISH, or both. DNA templates for these cases were prepared from formalin-fixed paraffin-embedded (FFPE) tissues to determine the HER2 copy number by ddPCR. ddPCR involved emulsifying hydrolysis probe–based PCR reaction mixtures containing the ERBB2 [v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); also known as HER2] gene and chromosome 17 centromere assays into nanoliter-sized droplets for thermal cycling and analysis. RESULTS: ddPCR distinguished, through differences in the level of HER2 amplification, the 10 HER2-positive samples from the 29 HER2-negative samples with 100% concordance to HER2 status obtained by FISH and IHC analysis. ddPCR results agreed with the FISH results for the 6 cases that were equivocal by IHC analyses, confirming 2 of these samples as positive for HER2 and the other 4 as negative. CONCLUSIONS: ddPCR can be used as a molecular-analysis tool to precisely measure copy number alterations in FFPE samples of heterogeneous breast tumor tissue.
- 1 June 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (6) , 991-994
Open AccessDroplet Digital PCR Measurement of HER2 Copy Number Alteration in Formalin-Fixed Paraffin-Embedded Breast Carcinoma Tissue
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) testing is routinely performed by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) analyses for all new cases of invasive breast carcinoma. IHC is easier to perform, but analysis can be subjective and variable. FISH offers better diagnostic accuracy and added confidence, particularly when it is used to supplement weak IHC signals, but it is more labor intensive and costly than IHC. We examined the performance of droplet digital PCR (ddPCR) as a more precise and less subjective alternative for quantifying HER2 DNA amplification. METHODS: Thirty-nine cases of invasive breast carcinoma containing ≥30% tumor were classified as positive or negative for HER2 by IHC, FISH, or both. DNA templates for these cases were prepared from formalin-fixed paraffin-embedded (FFPE) tissues to determine the HER2 copy number by ddPCR. ddPCR involved emulsifying hydrolysis probe–based PCR reaction mixtures containing the ERBB2 [v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); also known as HER2] gene and chromosome 17 centromere assays into nanoliter-sized droplets for thermal cycling and analysis. RESULTS: ddPCR distinguished, through differences in the level of HER2 amplification, the 10 HER2-positive samples from the 29 HER2-negative samples with 100% concordance to HER2 status obtained by FISH and IHC analysis. ddPCR results agreed with the FISH results for the 6 cases that were equivocal by IHC analyses, confirming 2 of these samples as positive for HER2 and the other 4 as negative. CONCLUSIONS: ddPCR can be used as a molecular-analysis tool to precisely measure copy number alterations in FFPE samples of heterogeneous breast tumor tissue.